From October 28 to 30, 2025, CPHI Worldwide Europe 2025, the world’s largest and most influential professional event in the pharmaceutical industry, was grandly held at Messe Frankfurt, Germany. This exhibition attracted 2,000 exhibitors and 62,000 professional visitors from more than 130 countries. As a top industry event held for 35 consecutive years, CPHI Worldwide Europe 2025 gathered top enterprises, decision-makers and innovative forces from the global industrial chain including APIs, biopharmaceuticals, biotechnology, contract development and manufacturing (CDMO), pharmaceutical machinery and packaging.

Against this background, Chengdu Olymvax Biopharmaceuticals Inc. (hereinafter referred to as “Olymvax”) made its debut at CPHI Europe 2025 with three marketed products and a number of key products under research for the first time, including Class 1.1 new drugs filling the world’s gaps, as an independent exhibitor. This is Olymvax’s first public display in the European market, marking a crucial step forward in the Company’s internationalization process and laying a solid foundation for the Company’s layout in the global vaccine market.

During the exhibition, the representative team of Olymvax received customer representatives from the Middle East, Thailand, India, Russia, Pakistan and other countries and regions. The two sides had in-depth exchanges on product technology, cooperation models and subsequent supply chain layout. After the exhibition, the relevant functional departments of Olymvax plan to quickly promote intended cooperation projects according to the specific situation of on-site negotiations, and continue to showcase the Company’s technical strength and product innovation achievements in subsequent international conferences and industry forums.

As a high-end platform gathering global pharmaceutical enterprises, CPHI Europe provides the Company with a valuable opportunity to communicate face-to-face with partners from all over the world, which is of far-reaching significance for expanding the international market and enhancing brand influence. The Company expects to further promote global cooperation in vaccine technology through this exhibition and jointly address challenges in the field of public health.